

Clinical trials of All mechanism for melanoma in all type of patients

TrialResults-center www.trialresultscenter.org

1 combined BRAF and MEK inhibition

Trial	Treatments	Patients	Trials design and methods
trametinib and dabrafenib vs dabrafenib			
Long , 2014 [NCT01584648] n=NA follow-up:	dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) versus dabrafenib and placebo	previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation	
Flaherty , 2012 [NCT01072175] n=NA follow-up:	dabrafenib (150 mg) plus trametinib (1 or 2 mg) versus dabrafenib monotherapy	patients with metastatic melanoma and BRAF V600 mutations	

References

Long, 2014:

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandal M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Pro Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med* 2014;371:1877-88 [[25265492](#)]

Flaherty, 2012:

Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* 2012;367:1694-703 [[23020132](#)]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.